Acne vulgaris, better known as acne, is the most common skin condition in the US, according to the American Academy of Dermatology (AAD), affecting up to 50 million Americans annually. About 85% of ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical ...

A few things happen when you get a corticosteroid injection at the dermatologist’s office. “We inject it into active inflamed ...

--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National ...

The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

TARRYTOWN, N.Y., Nov. 12, 2024 /PRNewswire/ -- A pivotal study led by renowned U.S. dermatologist Dr. Nazanin Saedi showcases the remarkable efficacy of the Aerolase Neo Elite ® 650-microsecond 1064nm ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

The acne also came back after treatment, which Brian says can happen up to 50 percent of the time. "A lot of people think it's a 100 percent success rate and then you're clear forever, and that's not ...

Previous associations between depression, suicidal behavior and the acne drug isotretinoin may be explained by presence of the acne itself, rather than treatment with the medication, according to ...